

REMARKS

Claims 1, 3, 5, 18, and 55-59 are pending in the instant application. By this Amendment, Applicants have amended the Sequence Listing to correct an obvious error in SEQ ID NO: 39, as discussed below and to include an inventor's name which was inadvertently omitted from the Listing. Applicants attach a substitute Sequence Listing incorporating these corrections, and respectfully request entry of the substitute Sequence Listing into the application. A substitute computer-readable form of the Sequence Listing is also submitted, and it is hereby stated that the content of the Sequence Listing information recorded in the computer readable form is identical to the Sequence Listing written on paper. Neither contains new matter.

Applicants also have amended Figures 5 and 6 to include sequence identifiers as suggested by the Examiner. Moreover, Applicants have made the same correction to SEQ ID NO: 39 in Figure 6 as that made in the Sequence Listing. Applicants have made no current amendments to the claims. The present Amendment does not introduce any new matter, and thus, its entry is requested.

Notice to Comply with Sequence Requirements

The Examiner indicated that he is still unable to identify which sequences are identified by which SEQ ID NOS and has thus now suggested introducing sequence identifiers directly into Figures 5 and 6.

In response, Applicants have amended Figures 5 and 6 as suggested by the

Examiner. Each sequence in each of these Figures is now clearly identified by SEQ ID NO. In addition, Applicants noticed an obvious error in SEQ ID NO: 39, as shown in the attached corrected copy of Figure 6, (which accompanies the separate letter requesting drawing changes). Specifically, the third codon in the TCRBV region of the nucleotide sequence for patient 40 is shown as "GCT." The figure also indicates, however, that the amino acid encoded by that codon is "V." The GCT codon of course actually encodes the amino acid "A," not "V." Accordingly, the proposed changes to Figure 6 also include the correct amino acid, ("A") in this portion of SEQ ID NO: 39. This correction has also been made to the Sequence Listing. In addition, the Sequence Listing includes the name of inventor Winfried Albert, which had been inadvertently omitted from the previous Listing. As the Official Filing Receipt indicates, Winfried Albert is an original named inventor, and thus no attempt is being made to change inventorship in any way by this correction to the Sequence Listing.

With the addition of the sequence identifiers to the Figure descriptions in the previous response, and the now further inclusion of the identifiers directly into the Figures themselves, Applicants maintain that the application remains in full compliance with the sequence rules.

In view of the above remarks and amendments, Applicants believe that the Examiner's concerns set forth in the April 21, 2003 Office Action and accompanying Notice to Comply with the Sequence Rules, have been fully overcome and that the present application is now in condition for allowance. The Examiner is invited to

telephone the undersigned if it is deemed to expedite allowance of the application.

Respectfully submitted,



Date: May 20, 2003

Patrick T. Skacel
Registration No. 47,948
Attorney for Applicants
Rothwell, Figg, Ernst & Manbeck, P.C.
1425 K Street, N.W., Suite 800
Washington, DC 20005
Telephone: (202) 783-6040
Fax: (202) 783-6031

Attachments:

Copy of Notice to Comply

Computer and Paper Copies of the substitute Sequence Listing

Letter requesting drawing changes, including drawings with proposed drawings in red ink

2923-393.am2